NasdaqGS - Delayed Quote USD

TherapeuticsMD, Inc. (TXMD)

1.9200 +0.0300 (+1.59%)
At close: April 24 at 4:00 PM EDT
1.8900 -0.03 (-1.56%)
After hours: April 24 at 7:23 PM EDT
Loading Chart for TXMD
DELL
  • Previous Close 1.8900
  • Open 1.8900
  • Bid 1.5900 x 100
  • Ask 2.1800 x 100
  • Day's Range 1.8600 - 1.9300
  • 52 Week Range 1.8600 - 4.7200
  • Volume 14,663
  • Avg. Volume 22,385
  • Market Cap (intraday) 22.142M
  • Beta (5Y Monthly) 1.04
  • PE Ratio (TTM) --
  • EPS (TTM) -0.7400
  • Earnings Date May 13, 2024 - May 17, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

www.therapeuticsmd.com

1

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TXMD

Performance Overview: TXMD

Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TXMD
14.67%
S&P 500
6.33%

1-Year Return

TXMD
48.66%
S&P 500
22.70%

3-Year Return

TXMD
96.72%
S&P 500
21.33%

5-Year Return

TXMD
99.08%
S&P 500
72.88%

Compare To: TXMD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TXMD

Valuation Measures

Annual
As of 4/23/2024
  • Market Cap

    21.68M

  • Enterprise Value

    25.36M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    15.08

  • Price/Book (mrq)

    0.74

  • Enterprise Value/Revenue

    19.48

  • Enterprise Value/EBITDA

    -3.34

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -7.96%

  • Return on Equity (ttm)

    -23.90%

  • Revenue (ttm)

    1.3M

  • Net Income Avi to Common (ttm)

    -7.7M

  • Diluted EPS (ttm)

    -0.7400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.33M

  • Total Debt/Equity (mrq)

    27.33%

  • Levered Free Cash Flow (ttm)

    -34.19M

Research Analysis: TXMD

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: TXMD

Fair Value

1.9200 Current
 

Dividend Score

0 Low
TXMD
Sector Avg.
100 High
 

Hiring Score

0 Low
TXMD
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
TXMD
Sector Avg.
100 High
 

People Also Watch